Tradestie Institutional Equity Comparison Engine
COCP vs AIM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
COCP Overall Edge
COCP Captures Institutional Edge (2โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cocrystal Pharma, Inc. Common Stock (COCP) driven by superior Growth & Margin, Momentum & Technical while AIM counters with relative strength in Valuation. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus AIM at 2.0x Forward P/E and -11724.2% operating margin (+4.0% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AIM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
AIM
COCP N/M vs AIM 2.0x Fwd P/E
Growth & Margin Winner
COCP
Op Margin -3063.6% vs -11724.2% ยท YoY +26.9% vs +4.0%
Momentum & Technical Winner
COCP
1Y -3.0% vs -90.9% ยท 52W Pos 19% vs 1%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
COCP
NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap
$19.6M
1M Return
-2.01%
1Y Return
-2.96%
Forward P/E
N/M
Unified AI Score
47.1 / 100
HOLD
Tech 51.0
Fund 48.0
Flow 50.0
Mom 54.0
AIM
NYSE American
AIM ImmunoTech Inc.
Biological Products, (No Disgnostic Substances)
$0.13
-7.1% 1D
Market Cap
$5.9M
1M Return
-20.64%
1Y Return
-90.89%
Forward P/E
2.0x
Unified AI Score
52.8 / 100
HOLD
Tech 54.0
Fund 57.0
Flow 50.0
Mom 68.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
COCP -2.96%
AIM -90.89%
Spread: +87.93 pp (COCP Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | COCP Revenue | AIM Revenue | COCP Op. Margin | AIM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -3132.4% | AIM |
| FY2019 | $10M | $0M | -737.4% | -8887.9% | COCP |
| FY2020 | $0M | $0M | -476.0% | -9295.7% | COCP |
| FY2021 | N/A | $0M | N/A | -13954.1% | AIM |
| FY2022 | N/A | $0M | N/A | -14129.8% | AIM |
| FY2023 | N/A | $0M | N/A | -15800.0% | AIM |
| FY2024 | N/A | $0M | N/A | -11630.6% | AIM |
| FY2025 | N/A | $0M | N/A | -13254.5% | AIM |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | COCP | AIM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $19.6M | $5.9M | Larger Scale | COCP |
| Trailing P/E Ratio Valuation | N/M | 2.0x | Lower Multiple | AIM |
| Forward P/E Ratio Valuation | N/M | 2.0x | Lower Multiple | AIM |
| Revenue Growth (YoY) Growth | +26.9% | +4.0% | Higher Growth | COCP |
| Operating Margin (TTM) Profitability | -3063.6% | -11724.2% | Higher Margin | COCP |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -311.7% | -2382.3% | Higher ROE | COCP |
| 52-Week Range Position Momentum | 19% ($1โ$2) | 1% ($0โ$2) | Stronger Trend | COCP |
| Beta / 30D Volatility Risk Regime | 1.04ฮฒ ยท 54% Vol | 0.32ฮฒ ยท 69% Vol | Lower Realized Risk | COCP |
| Unified Institutional Score Composite Signal | 47.1 / 100 (HOLD) | 52.8 / 100 (HOLD) | Higher Composite | AIM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full COCP vs AIM Buy Guide
COCP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
AIM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither COCP nor AIM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.